Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: trospium chloride Clear all
Not yet recruiting Phase 3 Interventional

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia

NCT07783373
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline-trospium chloride, Oral antipsychotics
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Suwanee, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Not yet recruiting Phase 4 Interventional

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

NCT06924255
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Xanomeline and Trospium Chloride
Drug
Lead sponsor
Collaborative Neuroscience Research, LLC
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
Bellflower, California • Garden Grove, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting No phase listed Observational

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

NCT07101094
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline and trospium chloride (X/T) therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Costa Mesa, California • San Jose, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

NCT00932022
View directory record Official record
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

NCT04227184
View directory record Official record
Conditions
Urgency Urinary Incontinence
Interventions
Trospium, Placebo oral tablet
Drug
Lead sponsor
Becky Clarkson
Other
Eligibility
60 Years and older · Female only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229
View directory record Official record
Conditions
Alzheimer Disease, Agitation
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
46
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

The Impact of Cobenfy Maintenance on Cocaine's Effects

NCT07624227
View directory record Official record
Conditions
Cocaine Use Disorder (CUD)
Interventions
Cobenfy, Placebo
Drug
Lead sponsor
Joshua A. Lile, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania
Interventions
KarXT, Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
52
States / cities
Glendale, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Not yet recruiting Early Phase 1 Interventional

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

NCT07721272
View directory record Official record
Conditions
Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions
Cobenfy KarXT pill (50/20 mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT07011745
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05304767
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711
View directory record Official record
Conditions
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline tartrate, Trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

NCT00801684
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 3, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

NCT05643170
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 3, 2026, 3:23 PM EDT
Active, not recruiting No phase listed Observational

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

NCT07571148
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT (xanomeline and trospium)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698
View directory record Official record
Conditions
Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

NCT00863551
View directory record Official record
Conditions
Elderly, Pharmacokinetics, Overactive Bladder
Interventions
Trospium Chloride
Drug
Lead sponsor
Allergan
Industry
Eligibility
65 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCT04659174
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 3, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 3:23 PM EDT